The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...

A few years later, a clinical trial of a myostatin inhibitor called stamulumab (MYO-029) developed by Wyeth (which was acquired by Pfizer in 2009) showed some promise in early trials but was ...

Myostatin inhibitors, designed to promote muscle growth ... This discovery paves the way for further research on natural variations in myostatin levels and their impact on the timing of puberty ...

Based on the trial results, Scholar Rock, is now seeking FDA approval for their myostatin inhibitor, which is based on a fundamental mechanism discovered by Lee. “I could not be more excited to ...

Myostatin inhibitors, designed to promote muscle growth ... This discovery paves the way for further research on natural variations in myostatin levels and their impact on the timing of puberty, ...